The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression
Cell Reports · 2024
DOI: 10.1016/j.celrep.2023.113587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Huanyu Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational and Environmental Health, the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Enviro…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Genome, Mitochondrial. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nonalcoholic steatohepatitis (NASH) is a metabolism-associated fatty liver disease with accumulated mitochondrial stress, and targeting mitochondrial function is a potential therapy. The mitochondrial genome-encoded bioactive peptide MOTS-c plays broad physiological roles, but its effectiveness and direct targets in NASH treatment are still unclear. Here, we show that long-term preventive and short-term therapeutic effects of MOTS-c treatments alleviate NASH-diet-induced liver steatosis, cellular apoptosis, inflammation, and fibrosis. Mitochondrial oxidative capacity and metabolites profiling analysis show that MOTS-c significantly reverses NASH-induced mitochondrial metabolic deficiency. Moreover, we identify that MOTS-c directly interacts with the BH3 domain of antiapoptotic B cell lymphoma-2 (Bcl-2), increases Bcl-2 protein stability, and suppresses Bcl-2 ubiquitination. By using a Bcl-2 inhibitor or adeno-associated virus (AAV)-mediated Bcl-2 knockdown, we further confirm that MOTS-c improves NASH-induced mitochondrial dysfunction, inflammation, and fibrosis, which are dependent on Bcl-2 function. Therefore, our findings show that MOTS-c is a potential therapeutic agent to inhibit the progression of NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Occupational and Environmental Health, the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi…
- State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
- State Key Laboratory of Cancer Biology, Department of Biopharmaceutics, Fourth Military Medical University, Xi'an, China; Translational Medicine Center, Shaanxi Provincial People's Hospital, Xi'an, China; The College of…
- State Key Laboratory of Cancer Biology, Department of Biopharmaceutics, Fourth Military Medical University, Xi'an, China; Translational Medicine Center, Shaanxi Provincial People's Hospital, Xi'an, China.
- State Key Laboratory of Cancer Biology, Department of Biopharmaceutics, Fourth Military Medical University, Xi'an, China.
- State Key Laboratory of Cancer Biology, Department of Biopharmaceutics, Fourth Military Medical University, Xi'an, China; Translational Medicine Center, Shaanxi Provincial People's Hospital, Xi'an, China. Electronic add…
Zitieren
APA
Lu, H., Fan, L., Zhang, W., Chen, G., Xiang, A., Wang, L., Lu, Z., & Zhai, Y. (2024). The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113587
Vancouver
Lu H, Fan L, Zhang W, Chen G, Xiang A, Wang L, et al. The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports. 2024. doi:10.1016/j.celrep.2023.113587
BibTeX
@article{Lu2024,
author = {Lu, Huanyu and Fan, Linni and Zhang, Wenli and Chen, Guo and Xiang, An and Wang, Li and Lu, Zifan and Zhai, Yue},
title = {The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2023.113587}
}
EUVIMED